Celularity Inc (CELU) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Celularity reported revenue of $26.6M, down 51.0% from $54.2M the year before. Net income was -$91.7M (a -345.4% net margin), or -$3.59 per diluted share. Gross margin was 24.4% and operating margin was -230.9%. Operating activities generated -$13.3M of cash, leaving -$13.4M of free cash flow. At fiscal year end, Celularity held $107.3M in total assets against $145.4M in total liabilities, including $6.2M of cash and equivalents.
Open the full interactive Celularity financials → Quarterly statements, key ratios, valuation history and price charts.
Celularity Key Stats
| Share Price | $1.42 |
|---|---|
| Market Cap | $43.0M |
| Revenue YoY Growth | -51.0% |
| 52-Week Range | $0.60 – $2.27 |
| Shares Outstanding | 29.1 million (basic, 2026 Q1) |
Celularity Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $21.3M | $18.0M | $22.8M | $54.2M | $26.6M |
| Cost of Goods Sold | $0 | — | — | — | — | — |
| Gross Profit | $0 | $11.7M | -$1.7M | $6.8M | $39.2M | $6.5M |
| Operating Income | -$4.2M | -$109.1M | -$25.6M | -$192.3M | -$38.4M | -$61.3M |
| Pre-Tax Income | -$2.4M | -$100.1M | $14.2M | -$196.3M | -$57.9M | -$91.7M |
| Income Tax | $191,644 | $20,000 | $13,000 | $10,000 | — | $3,000 |
| Net Income | -$2.6M | -$100.1M | $14.2M | -$196.3M | -$57.9M | -$91.7M |
| Diluted EPS | -$4.50 | -$14.90 | $0.90 | -$11.02 | -$2.64 | -$3.59 |
Celularity Quarterly Results
| 2025 Q2 | 2025 Q3 | 2025 Q4 | 2026 Q1 | |
|---|---|---|---|---|
| Revenue | $5.7M | $5.3M | $4.1M | $3.8M |
| Net Income | -$24.5M | -$23.1M | -$24.4M | $874,000 |
| Diluted EPS | -$1.02 | -$0.88 | -$0.95 | $0.02 |
Celularity Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $314,696 | $37.2M | $14.0M | $227,000 | $738,000 | $6.2M |
| Current Assets | $359,289 | $59.1M | $33.5M | $19.8M | $20.6M | $12.3M |
| Total Assets | $292.2M | $414.1M | $401.1M | $143.9M | $132.7M | $107.3M |
| Current Liabilities | $3.4M | $26.2M | $62.1M | $67.3M | $53.7M | $80.8M |
| Total Long-Term Debt | — | — | — | — | — | $33.8M |
| Total Liabilities | $14.2M | $314.7M | $202.2M | $102.9M | $123.8M | $145.4M |
| Shareholders' Equity | $5.0M | $99.4M | $198.9M | $41.0M | $8.8M | -$38.1M |
Celularity Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$1.2M | -$110.1M | -$137.9M | -$38.7M | -$6.4M | -$13.3M |
| Cash From Investing | $578,703 | -$5.9M | -$5.2M | -$4.0M | $514,000 | — |
| Cash From Financing | — | $98.6M | $119.8M | $24.1M | $6.7M | $18.6M |
| Free Cash Flow | — | -$116.3M | -$143.1M | -$39.7M | -$6.6M | -$13.4M |
Figures from Celularity's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Celularity financials page for every line item.
Celularity Company Profile
| Ticker | CELU |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Florham Park, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001752828 |
Frequently Asked Questions
What was Celularity's revenue in fiscal 2025?
Celularity (CELU) reported revenue of $26.6M for fiscal 2025.
What is Celularity's annual revenue history?
Celularity's annual revenue by fiscal year: 2020: $0; 2021: $21.3M; 2022: $18.0M; 2023: $22.8M; 2024: $54.2M; 2025: $26.6M.
What was Celularity's net income in fiscal 2025?
Celularity reported net income of -$91.7M for fiscal 2025.
What was Celularity's earnings per share (EPS) in fiscal 2025?
Celularity's diluted EPS was -$3.59 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Celularity generate in fiscal 2025?
Celularity generated -$13.4M of free cash flow in fiscal 2025.
What was Celularity's revenue last quarter?
In its most recent reported quarter (2026 Q1), Celularity reported revenue of $3.8M.
How much debt does Celularity have?
Celularity reported $33.8M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Celularity are outstanding?
Celularity reported a weighted average of 29.1 million basic shares outstanding in 2026 Q1.
What is Celularity's market cap?
Based on its latest closing price, Celularity (CELU) has a market capitalization of about $43.0M.
When does Celularity's fiscal year end?
Celularity's fiscal year end, as registered with the SEC, is December 31.
Where is Celularity headquartered?
Celularity lists its business address in Florham Park, New Jersey in its SEC filings.